95 related articles for article (PubMed ID: 26299852)
1. [Molecular biology of colorectal cancer in clinical practice].
Kit OI; Vodolazhsky DI
Mol Biol (Mosk); 2015; 49(4):531-40. PubMed ID: 26299852
[TBL] [Abstract][Full Text] [Related]
2. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
3. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.
Mármol I; Sánchez-de-Diego C; Pradilla Dieste A; Cerrada E; Rodriguez Yoldi MJ
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106826
[TBL] [Abstract][Full Text] [Related]
4. Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer.
Sideris M; Papagrigoriadis S
Anticancer Res; 2014 May; 34(5):2061-8. PubMed ID: 24778007
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
6. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
7. Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.
Murcia O; Juárez M; Hernández-Illán E; Egoavil C; Giner-Calabuig M; Rodríguez-Soler M; Jover R
World J Gastroenterol; 2016 Apr; 22(13):3516-30. PubMed ID: 27053844
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular features of young-onset colorectal cancer.
Ballester V; Rashtak S; Boardman L
World J Gastroenterol; 2016 Feb; 22(5):1736-44. PubMed ID: 26855533
[TBL] [Abstract][Full Text] [Related]
9. Personalizing therapy for colorectal cancer.
Wong A; Ma BB
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):139-44. PubMed ID: 24025538
[TBL] [Abstract][Full Text] [Related]
10. Molecular markers predictive of chemotherapy response in colorectal cancer.
Shiovitz S; Grady WM
Curr Gastroenterol Rep; 2015 Feb; 17(2):431. PubMed ID: 25663616
[TBL] [Abstract][Full Text] [Related]
11. Translating colorectal cancer genetics into clinically useful biomarkers.
Morley-Bunker A; Walker LC; Currie MJ; Pearson J; Eglinton T
Colorectal Dis; 2016 Aug; 18(8):749-62. PubMed ID: 26990814
[TBL] [Abstract][Full Text] [Related]
12. Role of Wnt/β-catenin signaling regulatory microRNAs in the pathogenesis of colorectal cancer.
Rahmani F; Avan A; Hashemy SI; Hassanian SM
J Cell Physiol; 2018 Feb; 233(2):811-817. PubMed ID: 28266708
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathological classification of colorectal cancer.
Müller MF; Ibrahim AE; Arends MJ
Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
[TBL] [Abstract][Full Text] [Related]
14. Current and future biomarkers in the treatment of colorectal cancer.
Cuyle PJ; Prenen H
Acta Clin Belg; 2017 Apr; 72(2):103-115. PubMed ID: 27917697
[TBL] [Abstract][Full Text] [Related]
15. Molecular markers and pathway analysis of colorectal carcinoma in the Middle East.
Beg S; Siraj AK; Prabhakaran S; Bu R; Al-Rasheed M; Sultana M; Qadri Z; Al-Assiri M; Sairafi R; Al-Dayel F; Al-Sanea N; Uddin S; Al-Kuraya KS
Cancer; 2015 Nov; 121(21):3799-808. PubMed ID: 26218848
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer.
Tanaka H; Deng G; Matsuzaki K; Kakar S; Kim GE; Miura S; Sleisenger MH; Kim YS
Int J Cancer; 2006 Jun; 118(11):2765-71. PubMed ID: 16381005
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic biomarkers for metastatic colorectal cancer].
Neumann JH
Pathologe; 2016 Nov; 37(Suppl 2):180-185. PubMed ID: 27638531
[TBL] [Abstract][Full Text] [Related]
19. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.
Carethers JM; Jung BH
Gastroenterology; 2015 Oct; 149(5):1177-1190.e3. PubMed ID: 26216840
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
